Enterprise Value to FCFF (EV/FCFF)
Free Cash Flow to The Firm (FCFF)
Abbott Laboratories, FCFF calculation
US$ in millions
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Item | Description | The company |
|---|---|---|
| FCFF | Free cash flow to the firm is the cash flow available to the Abbott Laboratories suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. | Abbott Laboratories FCFF decreased from 2022 to 2023 but then slightly increased from 2023 to 2024. |
Interest Paid, Net of Tax
Abbott Laboratories, interest paid, net of tax calculation
US$ in millions
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2 2024 Calculation
Interest paid, tax = Interest paid × EITR
= 604 × 21.00% = 127
Enterprise Value to FCFF Ratio, Current
Abbott Laboratories, current EV/FCFF calculation, comparison to benchmarks
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | 233,279) |
| Free cash flow to the firm (FCFF) | 6,828) |
| Valuation Ratio | |
| EV/FCFF | 34.16 |
| Benchmarks | |
| EV/FCFF, Competitors1 | |
| Cigna Group | 11.38 |
| CVS Health Corp. | 16.49 |
| Elevance Health Inc. | 17.29 |
| Intuitive Surgical Inc. | 131.54 |
| Medtronic PLC | 22.22 |
| UnitedHealth Group Inc. | 22.42 |
| EV/FCFF, Sector | |
| Health Care Equipment & Services | 22.36 |
| EV/FCFF, Industry | |
| Health Care | 23.08 |
Based on: 10-K (reporting date: 2024-12-31).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
Abbott Laboratories, historical EV/FCFF calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | 240,390) | 205,452) | 192,330) | 213,980) | 229,787) | |
| Free cash flow to the firm (FCFF)2 | 6,828) | 5,628) | 8,274) | 9,116) | 6,221) | |
| Valuation Ratio | ||||||
| EV/FCFF3 | 35.21 | 36.51 | 23.24 | 23.47 | 36.94 | |
| Benchmarks | ||||||
| EV/FCFF, Competitors4 | ||||||
| Cigna Group | 10.77 | 10.44 | 13.38 | 14.17 | 9.16 | |
| CVS Health Corp. | 15.91 | 11.96 | 10.00 | 10.30 | 9.42 | |
| Elevance Health Inc. | 15.57 | 14.19 | 13.32 | 12.74 | 6.04 | |
| Intuitive Surgical Inc. | 153.43 | 170.92 | 85.45 | 56.01 | 76.70 | |
| Medtronic PLC | 20.58 | 26.54 | 20.32 | 33.84 | 21.43 | |
| UnitedHealth Group Inc. | 20.57 | 17.59 | 19.30 | 22.21 | 15.82 | |
| EV/FCFF, Sector | ||||||
| Health Care Equipment & Services | 21.76 | 18.86 | 17.40 | 19.23 | 15.32 | |
| EV/FCFF, Industry | ||||||
| Health Care | 22.99 | 24.06 | 17.76 | 17.08 | 18.03 | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
3 2024 Calculation
EV/FCFF = EV ÷ FCFF
= 240,390 ÷ 6,828 = 35.21
4 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| EV/FCFF | Enterprise value to free cash flow to the firm is whole company valuation indicator. | Abbott Laboratories EV/FCFF ratio increased from 2022 to 2023 but then slightly decreased from 2023 to 2024. |